Hematopoiesis was investigated in a 14-yr-old girl who had a 2-yr history of stable asymptomatic pancytopenia and who was also heterozygous at the structural locus for glucose-6-phosphate dehydrogenase (G-6-PD). There was no morphologic or cytogenetic evidence for preleukemia and no suggestion of Fanconi anemia. In the skin and sheep erythrocytes-rosetted T lymphocytes, the ratio of G-6-PD A/B activities was 1:1. However, only type B activity was found in peripheral blood erythrocytes, granulocytes, and platelets. Most erythroid bursts and all granulocyte/macrophage colonies formed in methylcellulose culture were derived from the abnormal clone. These findings demonstrate that (a) some cases of pancytopenia are stem cell diseases that apparently develop clonally; (b) circulating differentiated cells originate from this clone; (c) despite a hypoproliferative anemia, the in vivo expression of presumably normal (nonclonal) progenitors is suppressed. In this patient, the relationship between clonal dominance and possible malignancy may be assessed prospectively.
Introduction
Studies of patients heterozygous for glucose-6-phosphate de- hydrogenase (G-6-PD)i suggest that many hyperproliferative hematologic disorders result from clonal expansion of a multipotent stem cell (1) (2) (3) . In this report, we document for the first time that clinically stable pancytopenia may also result from such a process.
The structural locus for G-6-PD is on the portion of the X chromosome that is randomly inactivated early in embryogenesis in somatic cells of females (1) . Therefore, in females heterozygous for the usual G-6-PD gene (GdB) and a variant such as GdA, some cells produce type B enzyme while others synthesize type A. A neoplasm arising in a single cell in a GdB/GdA heterozygote will manifest a single-enzyme type (e.g., B or A, but not both), whereas normal tissues will show both enzyme types.
Methods
Subject. A 12.5-yr-old black girl was found to have moderately severe pancytopenia in February 1981. There was no significant past medical or family history. Growth and development were normal (80th percentile for height; menarche at age 11). Physical examination showed short, slightly broad thumbs and great toes, clinodactyly of both fifth fingers, a bifid uvula, a submucous cleft palate, and mild ocular hypertelorism, anomalies not specifically associated with Fanconi anemia (4 G-6-PD analysis. The patient was determined to be heterozygous for G-6-PD by electrophoretic analysis of a full-thickness skin biopsy. Lymphocytes, granulocytes, erythrocytes, and platelets were separated (1 1) from serial peripheral blood samples obtained 2-3 mo following previous transfusions. The ratio of G-6-PD A/B activities was visually estimated following enzymatic staining of lysates separated by cellulose acetate (12) and starch gel electrophoresis (11) . A minor component contributing 5% to the total G-6-PD activity can be detected by this method (13) .
Cell culture. Mononuclear marrow cells were cultured for granulocyte/macrophage colony-forming units (CFU-GM), erythroid burstforming units (BFI-E), and erythroid colony-forming units (CFR-E) in the presence of 2.5% phytohemagglutinin-stimulated human lymphocyte-conditioned media and 1 unit/ml of partially purified human urinary Ep. CFR-GM were also cultured with 7.5% lymphocyte-conditioned media without Ep. At day 7, erythroid colonies were enumerated. At day 12-14 erythroid bursts and GM colonies were counted and individually harvested for G-6-PD analysis (14, 15) .
Lymphocyte preparation. T lymphocytes were rosetted with neuraminidase-treated sheep erythrocytes (E-rosetted T cells). Relative proportions of T helper and suppressor cells were assessed by indirect immunofluorescence following exposure to antibodies 66.1 (helper/inducer, equivalent to OKT-4) and 51.1 (cytotoxic/suppressor, equivalent to OKT-8) (16) . T cell subsets were separated on a fluorescence-activated cell sorter for G-6-PD analysis. E-rosette negative cells, which did not adhere to plastic after 2-h incubation, were considered B lymphocytes. 1-2% ofthis cell population were monocytes by Wright-Giemsa and nonspecific esterase stains.
Results
G-6-PD analysis ofblood cells (Table I) . Equal activities of G-6-PD types A and B were found in skin and E-rosetted T cells. In contrast, only type B activity was detected in preparations of erythrocytes, granulocytes, and platelets on six separate occasions. Although the helper/inducer to cytotoxic/suppressor T Discussion Cellular mosaicism for G-6-PD in this patient with hematologically stable pancytopenia offers a unique opportunity to study the mechanism ofmarrow failure. Circulating erythrocytes, granulocytes, and platelets had a single G-6-PD type (B) and, by inference, were derived from a single clone. Most BFU-E and CFU-GM also originated from this clone, suggesting that the pancytopenia was secondary to the clonal expansion of a myeloid stem cell. This mechanism is conceptually similar to that in the myeloproliferative diseases (1) and refractory acquired sideroblastic anemia (3). Yet, in contrast to these diseases, proliferation and differentiation ofthe abnormal clone in this patient were insufficient to support normal peripheral blood counts. Initially, presumably normal (G-6-PD type A) BFU-E matured in vitro. However, despite a hypoproliferative marrow, confirmed by morphologic and iron kinetic studies, and an elevated Ep level, circulating nonclonal erythrocytes were not seen. Since the electrophoretic techniques detect 5% of a minor enzyme component of a sample (13) , the failure to detect nonclonal erythrocytes could be explained if the in vivo differentiation of normal erythroid progenitors were suppressed. Alternatively, the patient may be an A-/B heterozygote. A-erythrocytes lose G-6-PD activity with age (13) and therefore might not contribute to the erythrocyte G-6-PD determination.
No presumably normal GM colonies were detected in culture. However, by analogy with chronic myelogenous leukemia, it is likely that normal multipotent stem cells exist. In five reported G-6-PD heterozygotes with chronic myelogenous leukemia only 2 of 1,308 GM colonies tested derived from the normal cell population (14) . Yet, in one patient, following aggressive chemotherapy, many nonclonal CFU-GM and BFU-E were detected (15) . If the clonal disorder in our patient represents a neoplastic transformation of a myeloid stem cell, then the neoplastic process directly inhibits the growth of normal stem cells. Circulating lymphocytes were also studied to determine if they originated from the dominant clone. E-rosette-positive T cells were not clonal. Though E-rosette negative, nonadherent cells were skewed towards G-6-PD type B, suggesting that some B-lymphocytes may derive from the dominant clone, it is likely that contamination of the sample by small numbers of monocytes, which have an extremely high G-6-PD activity per cell, distorted these results.
Of interest is the reversal ofthe helper/inducer to cytotoxic/ suppressor T cell ratio in this patient. As each T cell subset had equal activities of G-6-PD A and B, the imbalance of these populations did not result from direct clonal expansion. Whether the reversed T cell ratio in our patient is an epiphenomenon, is responsible for the suppression of normal stem cell growth (19, 20) , facilitated the clonal expansion of an abnormal myeloid stem cell, or represents a physiologic response controlling neoplastic expansion (21) is unclear. This latter possibility raises a theoretical problem, however, when one considers antithymocyte globulin therapy for patients with aplastic anemia.
Serial study will establish ifthe clonal disorder in this patient represents a neoplastic change, perhaps preleukemic, of a myeloid stem cell, or is a reflection of stem cell suppression or depletion following an unknown injury.
